When treated with this concentration of Leronlimab in the spreading assay, CD4+ T cell targets from CCR5 wild-type donors became fully resistant to infection with CCR5-tropic HIV while still supporting replication of CXCR4- and dual-tropic HIV, identical to the infection pattern observed with CD4+ T cell targets from a CCR5Δ32/Δ32 donor (Fig. 1a). Here, CXCR4 is linked to infection.